Vitiligo, a chronic acquired depigmenting disorder, affects 0.5%–2% of the global population and, although typically asymptomatic, often leads to substantial psychosocial consequences, including stigmatization, diminished self-esteem, and social withdrawal.1–3 Multiple studies documented a higher prevalence of psychiatric comorbidities, particularly anxiety and depression, among vitiligo patients versus the general population.3,4

While general dermatology instruments like the Dermatology Life Quality Index (DLQI) are widely used to assess disease burden, they may systematically underestimate vitiligo's specific psychosocial impact.5 These generic tools often emphasize physical symptoms such as pain or pruritus, largely irrelevant to vitiligo patients. To address these limitations, the Vitiligo-Specific Quality of Life instrument (VitiQoL)6 was developed as the first disease-specific questionnaire, offering targeted evaluation of emotional and social impairment unique to this condition. It was subsequently translated and validated in Brazilian Portuguese, ensuring cultural and linguistic appropriateness for the local population.7

Despite extensive international research on vitiligo's psychosocial impact, data from Brazilian referral centers remain remarkably scarce. This study aimed to comprehensively assess vitiligo patients' Quality of Life (QoL) using the VitiQoL instrument and systematically identify clinical and demographic variables associated with QoL impairment, emphasizing disease activity and progression ‒ dynamic factors often inadequately captured in cross-sectional assessments.

This cross-sectional study included 100 consecutive adult patients with clinically confirmed vitiligo, followed at the Dermatology Outpatient Clinic of Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo. Inclusion criteria were age ≥ 18-years, functional literacy in Brazilian Portuguese, adequate cognitive ability to complete questionnaires, and written informed consent. Patients with concurrent pigmentary disorders or other disfiguring dermatological conditions were systematically excluded to avoid potential confounding effects on body image perception and quality of life assessment.

All participants completed demographic questionnaires capturing age, sex, marital status, and educational attainment, and underwent a comprehensive clinical evaluation by dermatologists. Vitiligo subtype was meticulously classified according to Vitiligo Global Issues Consensus Conference criteria.8 Fitzpatrick skin phototype9 was systematically recorded, and disease extent was measured using the validated Vitiligo Extent Score (VES)10 via online visual assessment tools. Disease progression was rigorously categorized into five groups: “improving”, “stable for less than two years”, “stable for more than two years”, “worsening slowly”, and “worsening rapidly”, based on a comprehensive evaluation of lesion dynamics and clinical activity markers, including Köbner phenomenon, trichrome patterns, and confetti macules.8,11

QoL was assessed using the validated Brazilian Portuguese VitiQoL, a psychometrically robust 16-item instrument specifically designed for vitiligo patients.7 The VitiQoL ranges from 0 to 96, with higher scores indicating worse QoL, similar to the DLQI, whereas in other QoL questionnaires, such as the SF-36, AcneQoL, and WHOQOL-BREF, higher scores reflect better QoL. To minimize potential response bias and ensure participant privacy when reporting sensitive psychosocial aspects, all instruments were strictly self-administered. Clinical evaluation and VitiQoL application were performed on the same day to ensure data consistency.

Statistical analyses were conducted using STATA 11.0. Descriptive statistics were reported as means, medians, and 95% confidence intervals. Associations between VitiQoL scores and categorical variables were evaluated using the Kruskal-Wallis test, while Spearman's correlation coefficient was employed for continuous variables. A significance level of p < 0.05 was adopted for all statistical comparisons.

Study participants had a mean age of 50.9-years (SD = 16.0) and were predominantly female (71%) (Table 1). Generalized vitiligo represented the most common clinical form (76%), followed by acrofacial (11%), focal (7%), segmental (3%), indeterminate (2%), and mixed variants (1%). Most patients exhibited Fitzpatrick phototype IV (44%), consistent with Brazilian demographics. Mean disease duration was 17.8-years, highlighting vitiligo's chronic nature and sustained psychosocial burden. Regarding disease progression, 26% of patients were classified as “worsening rapidly” and 27% as “improving”, ensuring representation across the disease spectrum.

Mean VitiQoL score was 41.6 (maximum possible: 96). Female patients reported significantly greater QoL impairment than males (median: 43 vs. 32; p = 0.018), consistent with previously documented2 gender disparities in psychosocial impact (Table 2). Notably, married individuals demonstrated significantly worse QoL scores than unmarried participants (median: 51 vs. 37; p = 0.040). Although counterintuitive, this may reflect vitiligo's impact on intimate relationships, body image within partnerships, or concerns about partner acceptance. Importantly, the VES assessment tool does not separately evaluate genital involvement, which may partially explain this association and represents a limitation of current disease measurement instruments.

QoL outcomes did not differ significantly across educational levels, skin phototypes, or vitiligo subtypes, suggesting these factors have minimal influence on psychosocial burden. Similarly, disease duration showed no correlation with VitiQoL scores (rho = -0.13; p = 0.180), indicating that chronicity alone is not a primary determinant of emotional distress (Table 3). In stark contrast, disease activity demonstrated a profound association with QoL (p < 0.001). Patients classified as “worsening rapidly” exhibited the highest mean VitiQoL scores (59), while those categorized as “improving” had the lowest scores (24). Intermediate categories demonstrated a logical progressive pattern: “stable < 2-years” (47), “stable > 2-years” (39), and “worsening slowly” (37.5).

VES-derived total Body Surface Area (BSA) involvement demonstrated a weak but statistically significant correlation with VitiQoL scores (rho = 0.27; p < 0.05). Anatomical region-specific analyses revealed weak correlations for trunk (rho = 0.26), extremities (0.29), and hands (0.24), but surprisingly, no significant association with facial or pedal involvement. The absence of correlation between facial vitiligo and QoL impairment was particularly unexpected, given the face's visibility and social significance. This finding warrants further investigation and may reflect adaptation mechanisms, age-related acceptance, or cultural differences in facial appearance perception.

The highest individual VitiQoL item scores related to self-perceived disease severity and concerns about disease progression, emphasizing the emotional distress associated with unpredictability and perceived loss of control. This finding strongly supports targeting disease activity ‒ rather than merely extent ‒ as a primary therapeutic objective.

These results demonstrate that vitiligo's impact on quality of life is more profoundly influenced by subjective disease perception and dynamic progression patterns than by objective clinical parameters such as extent or chronicity. Treatment decisions should therefore systematically incorporate patient-reported outcomes, with explicit emphasis on halting disease progression as meaningful therapeutic goals. These findings provide compelling evidence for including patient-reported outcome measures in both clinical trials and routine dermatological practice. The widespread assumption that vitiligo is cosmetically benign and requires minimal intervention may contribute to systematic undertreatment and preventable psychological harm. Study limitations include a cross-sectional design precluding causal inference and single-center recruitment, potentially limiting generalizability.

In conclusion, this study provides novel data from a major Brazilian referral center, demonstrating vitiligo's significant impact on quality of life, particularly among women and patients experiencing disease progression. Surface area involvement alone proves insufficient for guiding evidence-based therapeutic decisions. Clinicians should consider not only vitiligo's visible manifestations but also its evolving clinical course and profound psychological consequences. Early recognition, empathetic care, and proactive treatment interventions may substantially improve patient well-being and long-term outcomes.